The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESC 2026 | Insights into the potential of CRISPR-based gene editing in ATTR-CM
Ronald Witteles, MD, Stanford University, Stanford, CA, discusses the potential of CRISPR-based gene editing as a one-time treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), highlighting its ability to achieve sustained TTR reduction. Dr Witteles also explores the key considerations for its future adoption in routine cardiology practice, including efficacy, durability, safety and patient acceptance. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
